الفهرس 
Radiolabeling study and purification of some anti-inflammatory agents for inflammation imaging
List of contentsOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
This study developed radiolabeled diclofenac and lornoxicam as inflammation imaging agents based on their anti-inflammatory characteristics. Radioiodinated diclofenac could be produced with a simple radioiodination reaction with high radiochemical yields of 98.3±0.5, with prolonged in-vitro and in-vivo stability. Biodistribution study of radioiodinated diclofenac showed that rapid distribution throughout the body and uptake in the sterile inflamed muscle was observed within 4 hours to be 29.4±0.5. It also shows rapid clearance from the blood. The high target/non-target ratio ({u2248}9.1) of radioiodinated diclofenac at 4 h p.i. is better than that of radioiodinated analgin. The preclinical biodistribution studies of Technetium-99m lornoxicam showed that the radiolabeled lornoxicam was potentially accumulated in inflamed muscle (6.3±1% at 2h p.i.). Due to both radiolabeledcompounds are stable in vitro, we can conclude that radiolabeled diclofenac and lornoxicam could be used as an imaging agent for inflammation with the ability of radioiodinated diclofenac to overcome all the drawbacks of radioiodinated analgin. As a result, radiolabeled diclofenac and lornoxicam could be introduced as inflammation imaging radiopharmaceuticals with advance over the radioiodinated analgin